1. Sargassum fusiforme polysaccharide partly replaces acarbose against type 2 diabetes in rats.
- Author
-
Li, Zhao-Rong, Jia, Rui-Bo, Wu, Juan, Lin, Lianzhu, Ou, Zhi-Rong, Liao, Bingwu, Zhang, Lixia, Zhang, Xun, Song, Guohui, and Zhao, Mouming
- Subjects
- *
TYPE 2 diabetes , *ACARBOSE , *SARGASSUM , *GUT microbiome , *STREPTOZOTOCIN , *BLOOD sugar - Abstract
The objective of present research was to explore whether Sargassum fusiforme polysaccharide (SFP) could partly replace acarbose against type 2 diabetes in rats. Results indicated that SFP co-administered with low-dose acarbose intervention typically mitigated diabetic symptoms and serum profiles and exhibited better anti-diabetic effects than single acarbose treatment in controlling fasting blood glucose, improving insulin resistance and mitigating kidney injuries. The RT-qPCR analysis indicated that SFP co-administered with low-dose acarbose administration distinctly activated the IRS/PI3K/AKT signaling pathway compared with single acarbose treatment. Moreover, the co-administration also restrained liver fat accumulation via affecting the expression of HMGCR and SREBP-1c genes. In addition, the 16S rRNA gene sequencing analysis indicated that SFP co-administered with low-dose acarbose significantly restored beneficial composition of gut flora in diabetic rats, such as the increase of Muribaculaceae , Lachnospiraceae , Bifidobacterium , Ruminococcaceae _UCG-014, Ruminococcus _1, Romboutsia , Eggerthellaceae , Alistipes and Faecalibaculum , and the decrease of Escherichia - Shigella. These results suggested that SFP, the novel natural adjuvant of acarbose, displayed the desirable benefits in minimizing the dose of drug, while improving the anti-diabetic efficiency. Unlabelled Image • SFP-ACAR typically mitigated diabetic symptoms and serum profiles. • SFP-ACAR showed better effects in controlling FBG, insulin, BUN and Cr levels. • SFP-ACAR distinctly restored beneficial composition of gut flora in diabetic rats. • SFP-ACAR improved IR by notably activating the IRS/PI3K/AKT signaling pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF